HCAR3 therapy (Immunoadaptive Cell Therapy)

N/A

Report date: 2025/06/11 10:35:12

Base Information

Drug NameHCAR3 therapy (Immunoadaptive Cell Therapy)
Drug Alias Nameanti-GD2 CAR T-cell (Immunoadaptive Cell Therapy)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionDisialoganglioside GD2 modulatorsImmunostimulantsT lymphocytes stimulants +[4] 
TargetsDisialoganglioside GD2
Therapy Area/IndicationsNeuroblastomaGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesImmunoadoptive Cell Therapy Pvt Ltd
China Registration ClassN/A

Develop Information

Active CompaniesImmunoadoptive Cell Therapy Pvt Ltd
Inactive CompaniesN/A
Active IndicationsNeuroblastomaGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A